Researchers reveal that the latanoprost ophthalmic solution Xalatan causes a marked and sustained reduction of intraocular pressure (IOP) after two years of treatment.

The results of this open-label study demonstrate that latanoprost, applied once daily as a 0.005% solution, is effective in the reduction of IOP in patients with ocular hypertension or open-angle glaucoma over a sustained period of time. Additionally, the long-term follow-up in the patient population studies has not revealed any previously unknown ocular or systemic side effects.

Xalatan is one of Pharmacia Corporation's top-selling global products.